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Background:  To accelerate the healing of diabetic wounds, various kinds of growth factors have been employed. It is the short 
half-life of administered growth factors in hostile wound beds that have limited wide-spread clinical usage. To overcome this 
limitation, growth factor gene therapy could be an attractive alternative rather than direct application of factors onto the wound 
beds. We administered two growth factor DNAs, epidermal growth factor (EGF) and vascular endothelial growth factor (VEGF) 
into a cutaneous wound on diabetic mice. We compared the different characteristics of the healing wounds. 
Methods:  Streptozotocin was injected intraperitoneally to induce diabetes into C57BL/6J mice. The ultrasound micro-bubble 
destruction method with SonoVue as a bubbling agent was used for non-viral gene delivery of EGF
828 and VEGF
165 DNAs. Each 
gene was modified for increasing efficacy as FRM-EGF
828 or minicircle VEGF
165. The degree of neoangiogenesis was assessed us-
ing qualitative laser Doppler flowmetry. We compared wound size and histological findings of the skin wounds in each group. 
Results:  In both groups, accelerated wound closure was observed in the mice receiving gene therapy compared with non treated 
diabetic control mice. Blood flow detected by laser doppler flowmetry was better in the VEGF group than in the EGF group. 
Wound healing rates and histological findings were more accelerated in the EGF gene therapy group than the VEGF group, but 
were not statistically significant. 
Conclusion:  Both non-viral EGF and VEGF gene therapy administrations could improve the speed and quality of skin wound 
healing. However, the detailed histological characteristics of the healing wounds were different. 
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INTRODUCTION 
Wound healing, which proceeds through a series of consecu-
tive, but overlapping stages, is characterized by the sequential 
movement of different cell populations into the wound site [1]. 
  At the molecular level, the acute wound healing response is 
characterized by changes in the composition and organization 
of the extracellular matrix (ECM) as well as the local profile of 
growth factors [2,3]. 
  Blood components are released into the wound site activat-
ing the clotting cascade. The resulting clot induces hemostasis 
and provides a matrix for the influx of inflammatory cells. Plate-
lets degranulate releasing alpha granules, which secrete growth 
factors such as: epidermal growth factor (EGF), platelet-de-
rived growth factor (PDGF), and transforming growth factor-
beta (TGF-β) [4]. 
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  With the assistance of platelet released vascular endothelial 
growth factor (VEGF) and fibroblast growth factor (FGF), en-
dothelial cells proliferate and angiogenesis ensues. This pro-
cess is essential for the synthesis, deposition, and organization 
of a new ECM [5]. 
  EGF, originally reported by Dr. Stanley Cohen [6,7], is se-
creted by platelets, macrophages, and fibroblasts. This growth 
factor acts in a paracrine fashion on keratinocytes [8,9]. In vi-
tro studies have shown that EGF is up-regulated after acute in-
jury significantly accelerating reepithelialization [10] and in-
creasing tensile strength of the wound [11]. 
  VEGF is produced by endothelial cells, keratinocytes, fibro-
blast, smooth muscle cells, platelets, neutrophils, and macro-
phages [12-17]. It is important in wound healing because it 
promotes the early events in angiogenesis, particularly endo-
thelial cell migration [18-20] and proliferation [21-25] as seen 
in several in vitro studies. Chronic wounds have areas of local 
skin ischemia making VEGF a possible therapeutic modality. 
  However, high blood glucose levels impair both granulocyte 
and neutrophil function, and chemotaxis, resulting in increased 
risk of infection. Inflammation is prolonged, angiogenesis is 
impaired and there is decreased synthesis of collagen [1]. 
  There are changes in the cellular infiltrate and extracellular 
matrix, with prolonged expression of fibronectin. Finally, there 
are fewer T cells and more macrophages persisting beyond the 
initial stages of healing [3]. 
  We have recently shown that the minicircle-VEGF
165 is ef-
fective for the healing of the skin wound of the diabetic mice 
[26]. 
  After the above study, we administered EGF using another 
gene therapy method. Therefore, this study was thus designed 
to report the different characteristics of two genes on the skin 
wound of diabetic mice. 
METHODS 
Plasmid construction 
Human EGF cDNA was a kind gift from Dr. Siu-Yuen Chan, 
University of Hong Kong. The pβ-EGF159 was constructed by 
using human mature EGF plasmid and human full length EGF. 
We did not construct the minicircle DNA (cDNA) by using of 
pβ-EGF159. In the case of VEGF
165, p2øC31-β-VEGF
165 was 
constructed for the production of minicircle DNA. The DNA 
fragment only contains the chicken β-actin promoter, VEGF
165 
cDNA. The SV40 poly adenylation signal sequence was excised 
with BglII and ClaI from the pβ-VEGF
165, and then bluntly li-
gated between the attB and attP sites of the p2øC31 plasmid, 
which was a kind gift from Dr. Mark A. Kay (Department of 
Genetics, Stanford University, CA, USA). 
Preparation of DNAs 
E. coli DH5α (Invitrogen, Carlsbad, CA, USA) was transformed 
by p2øC31-β-VEGF
165. A single colony of the transformants 
was grown at 37°C overnight (OD600=4.5–5.0). The 1 L of 
bacterial culture in the steady state was spun down in a clinical 
centrifuge (rotor JA-14, J2-MC centrifuge; Beckman, Fuller-
ton, CA, USA) at 20°C, 1,300×g for 15 minutes. The pellet was 
re-dissolved with 1 L of fresh LB broth (pH 7.0) containing 1% 
L-(+)-arabinose. The resuspended bacteria were incubated at 
30°C with constant shaking at 225 rpm for 2 hours. Subsequent-
ly, 1 L of fresh LB broth (pH 9.0) containing 1% L-(+)-arabi-
nose was added to the culture and the bacteria were cultivated 
for additional 2 hours at 37°C for the activation of the restric-
tion enzyme I-SceI. Super-coiled minicircle DNA was prepared 
from the culture, using plasmid purification kits from the Qia-
gen (Valencia, CA, USA). The contaminated endotoxin in the 
DNA preparation was removed by the AffinityPak Detoxi-Gel 
(Pierce, Rockford, IL, USA). 
Cell culture and in vitro transfection 
The human embryonic kidney (HEK293) cells, were purchased 
from ATCC (Manassas, VA, USA). HEK293 cells were main-
tained in Dulbecco’s Modified Eagle Medium (DMEM) sup-
plemented with 10% fetal bovine serum (FBS) in a 5% CO2 in-
cubator. 
SonoVue 
SonoVue microbubbling echo contrast agent that utilizes sul-
fur hexafluoride was purchased from Bracco Diagnostics, Inc. 
(Bracco, UK). 
  For the assessment of transfection by sonoporation, the cells 
were detached by trypsin-EDTA, washed twice in phosphate-
buffered saline, and resuspended with serum free media at 
2.0×10
5 cells/well in 48-well plate (Nunc, Rochester, NY, USA). 
The diameter of each well was 12.0 mm. After addition of mi-
crobubble, each plasmid encoding human EGF and VEGF 
was mixed with the cell supernatant (2 μg/well). Immediately 
after the addition of the mixture of plasmids and microbub-
bles, the cells were exposed to ultrasound with a 20% duty cy-
cle (Sonitron 1000; Rich Mar Inc., Inola, OK, USA) for 30 sec-228
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onds, using a 6.0 mm in diameter ultrasound probe. The ultra-
sound probe was immersed directly into the cell suspension 
without any contact to the surface of well. After exposure, the 
cell suspensions were harvested, separated by centrifugation, 
and plated in 6-well dishes. The cells were incubated for 48 
hours before ELISA. 
Comparison of minicircle VEGF with a typical plasmid 
with bacterial backbone 
To assay the efficiency of transfection by minicircle VEGF, 
branched polyethylenimine (BPEI, 25kDa; Sigma–Aldrich, St. 
Louis, MO, USA) was used as a gene carrier. The plasmid/BPEI 
complexes were prepared at a 10/1 N/P ratio and incubated for 
30 minutes at room temperature. The cells were washed twice 
with serum-free medium, and then 2 mL of fresh serum-free 
medium was added. The plasmid/BPEI complex was added to 
each well. The cells were then incubated for 4 hours at 37°C in 
a 5% CO2 incubator. After 4 hours, the transfection mixtures 
were removed and 2 mL of fresh medium containing FBS was 
added. The cells were incubated in a CO2 incubator for 48 hours. 
The cells and media were harvested for ELISA. 
ELISA 
EGF protein was measured using Quantikine human EGF ELI-
SA kit (R&D Systems, Minneapolis, MN, USA). EGF protein 
was measured using Quantikine human EGF ELISA kit (R&D 
Systems). 
  The secreted VEGF protein in the media was measured us-
ing Quantikine human VEGF ELISA kit (R&D Systems). 
Animals 
All animal procedures were approved by the Experimental An-
imal Committee at the Inje University. Two-week-old male 
C57BL/6J mice (20 to 30 g) were purchased from the Samtako 
(Animal Breeding Center, Osan, Korea) and housed in the 
pathogen-free condition and had ad libitum access to water 
and the standard mouse chow. Diabetes mellitus was induced 
by the single intraperitoneal injection (200 mg/kg) of strepto-
zotocin (STZ) [27]. Random blood glucose levels were mea-
sured 1 week after the first STZ injection using a glucometer 
(Accu-Check; Roche Diagnostics, Indianapolis, IN, USA). Mice 
that showed blood glucose levels over 200 mg/dL were consid-
ered as diabetic [28]. The mice were divided into four groups: 
control group (n=5), diabetic control group (n=5), EGF treat-
ed group (n=5), and VEGF treated group (n=5), and the pro-
cess was performed in triplicate.
Skin wounding 
Each animal was subjected to wounding (6 mm in diameter) 
by punch biopsy (Stiefel, Bad Oldesloe, Germany) on the skin 
of the back of the mouse. Briefly, prior to wounding, general 
anesthesia was induced by the administration of ketamine hy-
drochloride (100 mg/kg). The hair was shaved with the stan-
dard blade (no. 10). Then, the skin was disinfected with the 
povidone–iodine solution and wiped with sterile water. 
Gene delivery into diabetic mouse wound 
Diabetic C57BL/6J mouse with the back skin wound received 
a subcutaneous injection of PBS containing the mixture of 
minicircle-VEGF
165 (20 μg) and pβ-EGF
828 (20 μg) with mi-
crobubble solution (100 μg). Immediately after the injection, 
ultrasound (frequency, 1.0 MHz; duty, 20%; intensity, 2.0 W/
cm
2; time, 30 seconds) was applied to the injection site of the 
wound edge using a Sonitron 2000 ultrasonicator (Rich-Mar, 
Inola, OK, USA) with a probe of diameter 6 mm. 
Measurement of wound area and laser doppler imaging 
(LDI) 
The areas of the wounds were evaluated by densitometry (Multi 
Gauge V3.0 software; Fujifilm Life Science, Tokyo, Japan). The 
percentage wound closure was calculated as a ratio of final 
wound area to initial wound area. For the estimation of the 
skin blood flow, the wounds were scanned with a Laser Dop-
pler Imager (Periscan PIM II Laser Doppler Perfusion Imager; 
Perimed AB, Järfälla, Sweden) under the brief general anes-
thesia with inhalation of 1% to 2% isoflurane on the days 2, 6, 
and 12. The mice were placed on a light absorbing dark green 
background. The distance between the scanner head and the 
object was 20 cm. The Min and Max values were set at 0 and 8 
V, respectively. The perfusion scan image color scale displayed 
the lowest value in dark blue and the highest value in red, which 
represent the relative amount of skin perfusion. All mice were 
placed on a warming pad to maintain core body temperature 
between 36.8°C and 37.8°C during the scanning. 
Immunohistochemistry 
The tissue samples adjacent to the wounds were embedded in 
OCT compound (Tissue Tek; Sakura Finetek, Torrance, CA, 
USA). Transverse sections of 5 μm thickness were placed on 
polyl-lysine-coated slides. 229
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polyadenylation sequence. For the secretion of translated EGF, 
we added a furin protease recognition site to the N-terminal 
of EGF sequence (Fig. 1A). Likewise, we cloned the cDNA se-
quence of human VEGF
165 to generate pβ-VEGF (Fig. 1B). All 
plasmids DNA were transformed into DH5α, cultured to liter 
scale, and prepared using DNA maxi-prep kit (Qiagen, Valen-
cia, CA, USA). 
Gene delivery to HEK293 cells by sonoporation 
The human embryonic kidney (HEK) 293 cells in the presence 
of 2 μg of each plasmid were exposed to 1 MHz ultrasound 
with microbubble (10 mg/mL). With proper exposure intensi-
ty (2.0 W/cm
2) and duty (20%) the cell membrane was caused 
to be in a transiently porous state under ultrasound irradiation 
called “sonoporation.” The gene delivery by ultrasound has a 
major advantage of safety to the cell or tissue that exert the 
therapeutic effect of transgene. As shown in Fig. 1C and D, EGF 
and VEGF were measured from cell culture media (25 pg/mL 
Histology 
On day 12, wound tissues were fixed in 4% phosphate buffered 
formalin and then embedded in paraffin. From the paraffin-
embedded tissue blocks, 5 μm sections were cut and stained 
with hematoxylin and eosin (H&E) for the histological analy-
sis. 
Statistical analysis 
All the presented data were expressed as mean±standard de-
viation. The statistical significance was analyzed by the Stu-
dent’s t-test and ANOVA using the SPSS PC program (SPSS 
Inc., Chicago, IL, USA). 
RESULTS 
Plasmid construction 
The cDNA sequence of human mature EGF was inserted into 
pβ-plasmid, which had a chicken β-actin promoter and a SV40 
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Fig. 1.  Plasmid constructions and their expressions by ultrasound mediated gene delivery in human embryonic kidney (HEK) 
293 cells. (A) cDNA encoding human epidermal growth factor (EGF) with a N-terminal furin recognition sequence was inserted 
between EcoR I and Not I restriction sites under chicken β-actin promoter. (B) cDNA of human vascular endothelial growth fac-
tor 165 (VEGF
165) was inserted to produce pβ-VEGF
165. (C, D) Ultrasound mediated gene delivery in HEK 293 cells. The cells 
were exposed to 1 MHz US in the presence of 2 μg of each plasmid with a concentration of microbubble (10 mg/mL). Ultrasound 
intensity was 2.0 W/cm
2; ultrasound exposure time was 30 seconds; duty cycle was 20%. 
Bgl II
pβ-furin EGF 828
5,129 bp
EGF sequence
with furin recognition site
EcoR I
Not I
Cla I
Chicken β-actin promoter
Amp
R
Phage f1 region
SV40 polyA
pβ-VEGF
165
4.8 Kb
VEGF
165
EcoR I
Not I
Cla I
Chicken β-actin promoter
Bgl II
Amp
R
Phage f1 region
SV40 polyA230
Ko JH, et al.
Diabetes Metab J 2011;35:226-235 http://e-dmj.org
and 1.2 ng/mL, respectively) 48 hours after gene delivery in 
HEK293 cells. 
Production of minicircle-VEGF 
For the healing of chronic diabetic wound model, the initial 
rapid generation of blood circulation is known to be critical 
for the attraction of neutrophiles and monocytes to advance 
the repair process [29]. In the case of gene delivery of VEGF, 
we hypothesized that the earlier blood vessel formation and 
the initial increase of blood perfusion in the wound tissue 
would be necessary to accelerate the whole wound healing 
process. Therefore, we constructed a parent plasmid (p2øC31-
VEGF) to induce a minicircle form of DNA encoding VEGF 
that has minimal size of expression machinery to transgene 
expression of VEGF (Fig. 2A). By adding L-(+)-arabinose and 
adjusting pH and temperature to pH 9.0 and 37°C, respective-
ly, minicircle-VEGF DNA was recombinated out of the parent 
plasmid in DH5α. The remaining circular bacterial backbone 
DNA including an antibiotics resistance gene and a replication 
origin is linearized by homing endonuclease I-Sce I and de-
graded by bacterial exonucleases. The outcome of these pro-
cesses is the production of supercoiled minicircle-VEGF DNA 
(2.2 kb) that has largely reduced the size in comparison with a 
typical form of plasmid pβ-VEGF (4.8 kb) (Fig. 2B). The trans-
gene expression using minicircle-VEGF was 2 to 3 fold higher 
than a typical form of plasmid pβ-VEGF (Fig. 2C). This is con-
sidered to provide more rapid movement of minicircle DNA 
across the cytosol to the nuclear membrane than previously 
possible. Furthermore, minicircle DNA has no CpG island 
that stimulates unnecessary immune responses resulting in 
transgene quiescence. 
Measurement of wound area 
The results for the changes of the percentages of wound closure 
in both gene therapy groups are shown in Fig. 3. By day 6 post 
operation, all EGF and VEGF treated groups demonstrated 
Fig. 2.  Production of minicircle-vascular endothelial 
growth factor (VEGF) and the comparison of efficiency to 
a typical form of plasmid (pβ-VEGF) containing of bacteri-
al backbone using branched polyethylenimine (BPEI) as a 
gene carrier in human embryonic kidney (HEK) 293 cells. 
(A) p2øC31-β-VEGF
165 the expression cassette from pβ-
VEGF
165 was excised by restriction enzymes and bluntly li-
gated between attB and attP site of p2øC31 vector, which 
contains phi-C31 integrase and I-SceI homing endonucle-
ase. (B) Minicircle-VEGF
165. (C) Minicircle-VEGF
165 
showed 2 to 3 folds higher transfection efficiency in HEK 
293 cells. 2×10
5 cells of HEK293 were treated for 4 hours 
with plasmid DNA (pβ-VEGF
165 or Minicircle-VEGF
165) 
complexed with branched polyethylenimine (BPEI, 25 kDa, 
N/P ratio 10:1). VEGF concentrations in the culture media 
were measured by ELISA. 
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complete closure of the wounds in contrast to diabetic control 
with a mean percent closure below 70%. The differences among 
the groups were not statistically significant. 
LDI 
The differences of wound perfusion were monitored by non 
invasive LDI at day 2 and 6 (Fig. 4). In comparison with the 
EGF group, the minicircle-VEGF DNA treated diabetic mice 
group showed increased blood flow in the wound area. Skin 
perfusions were gradually decreased after day 12 (data not 
shown). 
Histological findings 
Both EGF and VEGF gene therapy could improve the speed 
and quality of skin wound healing. The detailed histological 
characteristics of healing wounds were different. The histology 
of biopsied wound tissue at day 12 in each group is shown in 
Fig. 5A. The wound of diabetic control shows severe edema 
and a disorganized pattern with heavy infiltration of inflam-
matory cells. In minicircle-VEGF treated group, wound resto-
ration is considered to be caused mainly by new blood vessel 
formation. Contrary to minicircle-VEGF, the EGF treated 
group, demonstrated epidermal reorganization that has com-
pletely restored the normal wound microarchitectures (Fig. 
5B) without observation of excessive increase of blood perfu-
sion (Fig. 4). 
DISCUSSION 
Diabetic foot ulcers (DFUs), one of the most common compli-
cations of diabetes, are a leading cause of hospitalization for 
diabetic patients. For a patient living with diabetes, the lifetime 
risk of developing a DFU is estimated to be 25% [30,31]. The 
prevalence of DFUs causes significant health care resources to 
be spent on the management of wounds. The interventions in-
clude emergency room visits, antibacterial medications, am-
putations, and a multitude of other therapies directed at non 
healing wounds. Therefore, many growth factors affecting 
wound healing are studied. 
  In 2004, one growth factor, topically applied recombinant 
PDGF, is currently approved by the US Food and Drug ad-
ministration for the treatment of diabetic foot ulcers. [30] 
However, its clinical success is limited in part by the need for 
daily application. There is a hostile proteolytic wound environ-
ment in which the protein is applied. A study about the sus-
tained effect and therapeutic potency is being performed. 
  There were many previous studies using VEGF and EGF. 
Angiogenesis is necessary for granulation tissue formation as 
well as for providing oxygen and nutrition to wounds [32]. In-
adequate angiogenesis in diabetic patients inhibits wound 
healing. VEGF is one of the most potent growth factors in 
stimulating angiogenesis. It triggers endothelial cell division, 
chemotaxis, and vascular permeability [33]. VEGF acts in a 
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Fig. 3.  Wound size comparison by ultrasound mediated gene delivery of epidermal growth factor (EGF) and vascular endothe-
lial growth factor (VEGF). (A) Growth factor gene delivery by sonoporation enhanced the progress of wound closure in diabetic 
mice to non-diabetic normal control group. (B) Average areas (in pixels) of wound that received ultrasound mediated gene deliv-
ery of EGF and VEGF were significantly reduced to non-diabetic control mice by day 12 post operation. C, control; DC, Diabetic 
(DM) control; DE, DM+EGF; DV, DM+VEGF.
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paracrine manner on dermal microvessels and endothelial 
cells. It also promotes the production of nitric oxide, which 
enhances collagen deposition. Previous studies with VEGF 
have demonstrated its efficacy in ischemic heart disease [34]. 
However, the increase in reepithelialization by VEGF
165-treated 
wounds has been reported [35]. Data from this study, con-
firmed by histology, showed the improvement in reepithelial-
ization. In previous studies, the more rapid maturation of 
granulation tissue in the VEGF
165-treated wound was shown to 
have more organized collagen fiber bundles deposited in gran-
ulation tissue. However, in this study, the greater cell density 
in the granulation tissue and healed tissue was observed in the 
EGF-treated group. 
  In addition, there were many studies using recombinant hu-
man EGF to enhance the healing effect on the chronic diabetic 
foot in human [36]. Various routes of administration have 
been used for delivering genes to the chronic wound. The ad-
vent of new topical agents has broadened the treatment ap-
proaches to wound healing. However, in the case of a full thick-
ness wound, the wound healing process might be delayed by 
using only topical application. When an intralesional infiltra-
tion of EGF was done, the wound size reduction time was ac-
celerated [36]. Abundant functional capillaries started to 
emerge and vascular endothelial nuclei were clearly less hy-
pertrophic. 
  In the present study, the improvement of wound healing 
time and wound reepithelization were similar in both groups. 
However, the detailed characteristics were different. In the 
VEGF treated diabetic group, LDI showed improved blood 
perfusion at the wound site, but ECM reorganization was more 
immature than the EGF treated group. 
  On the other hand, blood perfusion was not different from 
the control group in the EGF treated group, but ECM reorga-
nization was markedly improved. The EGF treated group 
demonstrated an increased amount of mature collagen com-
pared to the VEGF group. 
Control DM control DM + EGF
828 DM + VEGF
165
2 days
6 days
8 days
Fig. 4.  Blood perfusion in the wound tissue was significantly increased by ultrasound mediated gene delivery of growth factors 
to diabetic mice. The laser doppler imager (PeriScan) used in this study was employed for the visualization of blood perfusion. 
Red color represents high blood perfusion in the wound site. At the 6th day post operation, a significant increase of blood perfu-
sion was observed in diabetic (DM) mice group that received vascular endothelial growth factor (VEGF) gene delivery. 233
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  Jazwa et al. [37] demonstrated that combined VEGF and 
EGF gene transfer into the wound improves wound healing in 
diabetic mice. In this study, authors concluded that VEGF 
might increase the migration of diabetic fibroblasts cultured 
in high glucose concentration through FGF4-mediated up-
regulation of one of the VEGF receptors, Flt-1 (VEGF-Recep-
tor 1). We did not try the combined gene transfer into the 
wound, but it needs further evaluation. The combined gene 
therapy could be explained as a synergistic effect or a side ef-
fect. 
  We used a nonviral gene delivery system. When choosing 
appropriate biomaterials during the design of a delivery vehi-
cle, several factors must be considered [38,39]. These factors 
include predictability, accessibility, and safety issues. We fo-
cused on the safety issues. The efficacy of nonviral gene deliv-
ery is lower than the viral system, but the safety is most impor-
tant factor. 
  One of the limitations of our study is that we used different 
delivery system in each group. There is the structural difference 
between VEGF and EGF DNAs. Second, we administrated the 
same dose of DNAs but we could not identify that the dose 
acts with the same efficacy. Therefore, if we injected the same 
dose, the effect could be different. Third, we regret that we did 
not perform the collagen stain in the VEGF group, since we 
were unable to compare the efficacy of reepithelization between 
two groups.
  In conclusion, VEGF enhances the neoangiogenesis, but 
was not effective on maturation of organized reepithelization. 
The neoangiogenesis induced by EGF was not dominant, but 
it enhanced the maturation of organized reepithelization.
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